Merck, Eisai Kidney Cancer Drug Trial Faces Setback

Merck and Eisai have encountered a setback in a late-stage clinical trial for their Keytruda regimen aimed at treating kidney cancer. The specific details of the trial's outcome were not provided in the source material. This development could impact the future of this particular cancer treatment and potentially affect the companies' oncology pipelines. Further information regarding the trial's results and the companies' next steps is anticipated.